Navigation Links
Perrigo Announces Arrival of the FDA for Reinspection Related to the Allegan Facility Warning Letter

ALLEGAN, Mich., March 1, 2011 /PRNewswire/ -- Perrigo (Nasdaq: PRGO;TASE) today announced that, as part of the anticipated follow-up to the warning letter Perrigo received on April 30, 2010, the Detroit Office of the Food and Drug Administration (FDA) has arrived at their Allegan facility for the re-inspection.  

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is the world's largest store brand manufacturer of OTC pharmaceutical products and infant formulas. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 26, 2010, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Perrigo
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
2. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
3. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
4. Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam
5. Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009
6. Perrigo Company Announces Dividend Increase
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010
9. Perrigo Company to Present at the 28th Annual J.P. Morgan Healthcare Conference
10. Perrigo Company To Present at the Sidoti Emerging Growth Conference
11. Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015  Eyeon Therapeutics has ... dry eye treatments based on a charged hydrophilic ... delivery CDMO.  The product has been shown to ... previously published.  Mark Mitchnick , MD, CEO ... protection to additional polymers in conjunction with a ...
(Date:12/1/2015)... , December 1, 2015 --> ... report "Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, ... Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020", ... to reach USD 73,529.2 Million by 2020 from USD 40,281.6 ... to 2020. Browse 37 ...
(Date:12/1/2015)... HERTFORDSHIRE, England , BANGALORE, India ... 2015  Mylan N.V. (NASDAQ, TASE: MYL) today announced ... upon regulatory approval and for developing country markets funded ... + Lamivudine 300 mg + Efavirenz 400 mg) for ... Clinton Health Access Initiative (CHAI) to develop TLE400. The ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today announced that ... Business Awards under the New Products and Services category for its innovative product ... management software that helps labs organize data and track samples with storage ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, ... a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program ... as a finalist in the category of Digital Solutions for its innovative, industry-leading ...
(Date:12/1/2015)... ... 01, 2015 , ... TCS Healthcare Technologies (TCS), a leading ... arenas, is pleased to announce that VIP Care Services, a Caprock Health Group ... ACUITY Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY ...
Breaking Medicine News(10 mins):